Does early nirsevimab reduce wheezing in French kids?
Part of Lungs & breathing clinical trials.
This study looks at French health records to see if giving nirsevimab to babies early in life reduces wheezing (a whistling sound when breathing) during preschool years. It compares babies who got the shot with those who did not.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child was born between February 6, 2023 and January 31, 2024.
- Your child was born in mainland France (not in overseas territories).
- Your child is not a same-sex twin (twins with different sexes are fine).
- Your child did not receive an RSV vaccine during pregnancy from their mother.
- Your child did not receive palivizumab (Synagis) to prevent RSV.
- Your child did not have wheezing or an RSV lung infection requiring hospital care before getting nirsevimab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how different pregnancy and birth factors may contribute to airway inflammation in infants who wheeze or have lung conditions. It may help researchers understand why some babies get ongoing breathing problems and how early influences could be linked.
This trial tests giving a medicine called nirsevimab to newborns and a possible vaccine to pregnant mothers to prevent RSV, a serious lung infection in babies. It checks if combining both is safe and works better than nirsevimab alone.
This trial looks at how well the drug nirsevimab works for babies hospitalized with RSV bronchiolitis. It also studies the body's immune response and the baby's environment. The goal is to see if nirsevimab can help infants recover from this serious lung infection.
This study looks at whether the drug nirsevimab can reduce hospitalizations caused by RSV (a common respiratory virus) in babies under 1 year old. If your baby has a lung infection like bronchiolitis or pneumonia, this trial may help understand how well the medicine works.
This study looks at how well the new nirsevimab vaccine works against bronchiolitis in babies. If your infant has their first bout of bronchiolitis and gets a nose swab, they may be able to help researchers understand how the virus spreads and how to better protect other babies.
This study tests if the medicine Nirsevimab can help prevent severe RSV (a common winter virus) in infants in Chile. It is for babies born at specific times in 2023–2024, especially those born early or with health problems.
Hear when a new Asthma Childhood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.